🔎 Trials Near Me

Hjem › Øsofagus-adenocarcinom › Texas

Øsofagus-adenocarcinom kliniske forsøg i Texas

19 studier for Øsofagus-adenocarcinom søger deltagere på steder i Texas.

Byer i Texas

Officiel studietekst (engelsk)

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06203600

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  • Parkland Memorial Hospital, Dallas
  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • og 3 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT05677490

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

  • The University of Texas MD Anderson Cancer Center - Conroe, Conroe
  • University of Texas MD Anderson Cancer Center, Houston
  • The University of Texas, MD Anderson Cancer Center - West Houston, Houston
  • og 3 flere
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT07090499

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  • The Methodist Hospital Research Institute, Houston
  • The University of Texas MD Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT06324357

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  • Texas Oncology - Amarillo Cancer Center, Amarillo
  • Texas Oncology-Austin Central, Austin
  • Texas Oncology, Beaumont
  • og 4 flere
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07221149

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

  • US Oncology Investigational Products Center (IPC), Irving
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07392892

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

  • START Dallas Fort Worth, Fort Worth
  • MD Anderson, Houston
  • NEXT Oncology Houston, Houston
  • og 1 flere
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07277413

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

  • Baylor University Medical Center, Dallas
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT06732388

Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia

  • Baylor University Medical Center, Dallas
  • The University of Texas MD Anderson Cancer Center, Houston
Rekrutterer
Alder 18 til 89 · Alle køn · Opdateret 11. sep. 2026 · NCT05753748

A Study of KK2269 in Adult Participants With Solid Tumors

  • The University of Texas Southwestern Medical Center, Dallas
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 10. sep. 2026 · NCT06266299

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  • Research Site, Dallas
  • Research Site, Dallas
  • Research Site, Houston
  • og 1 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT07431281

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

  • Normunity Investigational Site, Dallas
  • Normunity Investigational Site, Houston
  • Normunity Investigational Site, San Antonio
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 18. aug. 2026 · NCT07182149

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  • Texas Oncology - West Texas, Amarillo
  • Texas Oncology, P.A., Dallas
  • Texas Oncology Gulf Coast, Pearland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 5. aug. 2026 · NCT06330064

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

  • Texas Oncology - Central South, Austin
  • START San Antonio, LLC., San Antonio
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 15. jul. 2026 · NCT06657144

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • Oncology Consultants, PA, Houston
  • Oncology Consultants, PA., Houston
  • The University of Texas M.D. Anderson Cancer Center, Houston
  • og 5 flere
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 6. jul. 2026 · NCT04389632

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

  • Research Site, San Antonio
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 12. jun. 2026 · NCT07284186

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

  • MDACC, Houston
  • NEXT Dallas, Irving
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 8. maj 2026 · NCT05954312

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

  • M D Anderson Cancer Center, Houston
RekruttererFase 2
Alder 18 til 79 · Alle køn · Opdateret 15. apr. 2026 · NCT03161522

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

  • VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas
  • Michael E. DeBakey VA Medical Center, Houston, TX, Houston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 5. nov. 2025 · NCT05563766

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.